Tag: Antibiotic spectrum

Cefepime, a potent fourth-generation cephalosporin, is a key antibiotic in treating serious aerobic infections, yet its activity against anaerobes like *Bacteroides* is notoriously poor. This limited spectrum necessitates the addition of an anaerobic agent, most commonly metronidazole, when treating infections with a mixed aerobic-anaerobic profile.

*Pseudomonas aeruginosa* is a formidable opportunistic pathogen, and resistance to fluoroquinolones, the only oral therapy for it, is increasingly prevalent [1.4.2, 1.4.3]. This raises a critical question for clinicians: **Does gatifloxacin cover pseudomonas** effectively in clinical settings?

Aztreonam is the first and only member of the monobactam class of beta-lactam antibiotics available in the United States [1.2.2, 1.2.3]. This article answers 'What kind of antibiotic is aztreonam?' by detailing its targeted action and uses.

First developed in the 1960s with the discovery of nalidixic acid, fluoroquinolones are a class of broad-spectrum antibiotics with bactericidal action that inhibit bacterial DNA synthesis. To understand their clinical use, it is essential to know what bacteria do fluoroquinolones cover, as their spectrum of activity has evolved significantly across different generations.

In 2017, there were an estimated 119,247 *Staphylococcus aureus* bloodstream infections in the United States, leading to nearly 20,000 deaths [1.11.3]. This highlights the need for potent antibiotics. So, **what is vancomycin only effective against?** This powerful glycopeptide antibiotic is a narrow-spectrum agent used almost exclusively against Gram-positive bacteria [1.2.1, 1.3.5].